Anti-IL-17A and anti-IL-17F (eg, bimekizumab), anti-IL-17RA (eg, brodalumab) IL-17A, IL-17F, IL-17E (or IL-25) Neutrophils, monocytes, macrophages, mast cells, endothelial cells, fibroblasts, ILC2 Might inhibit neutrophil recruitment and detrimental inflammation in severe COVID-19; and by acting on IL-25, brodalumab could also inhibit ILC2 differentiation Might favour fungal and bacterial infections